6483.TWO Original BioMedicals Co., Ltd.
- Market cap
- TWD 1.02B
- P/E
- -
- P/B
- 9.36x
- ROE
- -64.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6483.TWO undervalued?
Graham numberThe Graham number of Original BioMedicals Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Original BioMedicals Co., Ltd. fundamental analysis
No fundamental analysis for Original BioMedicals Co., Ltd. yet.
Original BioMedicals Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Original BioMedicals Co., Ltd.
Original BioMedicals Co., Ltd. engages in the development of drugs in Taiwan. The company develops OBM-A01, a radiation injury prevention and therapeutic drug for the treatment of acute radiation injuries, including nuclear radiation and solar radiation exposure in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; CCM-CL, a cyclic polypeptide antibiotic; and Iron Dextran, an injection for the treatment of iron deficiency. It also provides…
Full company profileOriginal BioMedicals Co., Ltd. financial statements
Original BioMedicals Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | - | - | 107K | 43.0K | 0.00 | 381K |
| Gross Profit | - | -11.7M | -8.61M | 95.0K | 35.0K | -8.40M | 306K |
| Operating Income | -38.9M | -33.7M | -32.7M | -40.2M | -59.3M | -78.3M | -105M |
| EBITDA | -25.8M | -21.4M | -23.9M | -31.2M | -49.8M | -65.7M | -92.1M |
| Net Income | -37.7M | -34.7M | -33.9M | -40.3M | -59.7M | -75.0M | -102M |
| EPS | -1.57 | -1.26 | -0.81 | -0.86 | -1.21 | -1.14 | -1.52 |
| Balance Sheet | |||||||
| Total Assets | 93.9M | 67.4M | 137M | 98.0M | 371M | 279M | 184M |
| Total Liabilities | 33.4M | 29.4M | 28.3M | 28.9M | 42.1M | 24.1M | 26.1M |
| Shareholders' Equity | 60.5M | 38.0M | 109M | 69.2M | 329M | 255M | 158M |
| Cash & Short-term Investments | 22.8M | 8.10M | 83.3M | 48.9M | 328M | 241M | 134M |
| Total Debt | 23.6M | 23.6M | 20.7M | 19.9M | 16.2M | 12.0M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -26.4M | -23.9M | -24.9M | -30.4M | -29.5M | -84.1M | -96.0M |
| Capital Expenditure | 0.00 | 0.00 | 1.92M | 467K | 311K | 1.84M | 949K |
| Free Cash Flow | -26.4M | -23.9M | -26.9M | -30.9M | -29.8M | -85.9M | -97.0M |
| Ratios | |||||||
| ROE | -62.2% | -91.5% | -31.1% | -58.2% | -18.2% | -29.4% | -64.3% |
| ROA | -40.1% | -51.6% | -24.7% | -41.1% | -16.1% | -26.8% | -55.2% |
| Net Profit Margin | - | - | - | -37,642.1% | -138,746.5% | - | -26,643.0% |
| Debt to Equity | 0.39x | 0.62x | 0.19x | 0.29x | 0.05x | 0.05x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Original BioMedicals Co., Ltd. dividends
Original BioMedicals Co., Ltd. has not paid dividends in the last 7 fiscal years.
Who owns Original BioMedicals Co., Ltd.
Ownership data of Original BioMedicals Co., Ltd. is not available yet.
Original BioMedicals Co., Ltd. company profile
- Company name
- Original BioMedicals Co., Ltd.
- Ticker
- 6483.TWO
- ISIN
- TW0006483001
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 25
- Fiscal year end
- December
- Address
- No. 9, Nanke 2nd Road, Tainan City, Taiwan, 744092
- Phone
- 886 6 505 5433
- Website
- i-obm.com
About Original BioMedicals Co., Ltd.
Original BioMedicals Co., Ltd. engages in the development of drugs in Taiwan. The company develops OBM-A01, a radiation injury prevention and therapeutic drug for the treatment of acute radiation injuries, including nuclear radiation and solar radiation exposure in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; CCM-CL, a cyclic polypeptide antibiotic; and Iron Dextran, an injection for the treatment of iron deficiency. It also provides NE (vitamin C+E) and NE Butorphanol, as well as technical services. Original BioMedicals Co., Ltd. was incorporated in 2011 and is based in Tainan City, Taiwan.
Original BioMedicals Co., Ltd. management
7- Dr. Cliff C. Wang Ph.D.CEO, CRO & Director
- Lawrence H. T. TangChief Financial Officer
- Hsiao-Pao YenCOO & Director
- Mr. Duncan Chen MSCTO & Director
- Ms. Cecilia HungDirector of Development
- Dr. Alan Liss Ph.D.Senior Vice President · born 1948
- Gan Xiao PingHead of Clinical Research Department